dostarlimab news

All news on dostarlimab (also known as Jemperli): plants, production capacities, investments and involved companies.

13 July 2026

GSK’s Jemperli shows sustained clinical complete responses in dMMR/MSI‑H locally advanced rectal cancer

Interim phase II results met primary endpoint (cCR12); trial suggests some patients may avoid chemo, radiation and surgery. Data to be shared with regulators including for US accelerated review.

Who will be producing dostarlimab in the future?

Find out with chemXplore Alpha

Learn more